White Light - SR-17 Tablets [10ct]

White Light SR-17 is a synthetic G-protein-biased partial agonist of the mu-opioid receptor (MOR), first described by Laura Bohn and colleagues at the Scripps Research Institute in 2017 and patented in 2016. It represents a distinct class of opioid receptor ligands developed to probe the functional consequences of biased MOR signaling.

Mechanism of Action

• G-Protein Biased Agonism — SR-17018 demonstrates strong selectivity for G-protein signaling over β-arrestin2 recruitment at the MOR, with an 80–100 fold bias factor relative to the reference agonist DAMGO.
• Non-Competitive Binding Profile — Exhibits non-competitive MOR agonism with nearly irreversible receptor binding characteristics, yet remains fully reversible by antagonists such as naloxone — suggesting allosteric site interaction rather than classical orthosteric binding.
• Partial Agonist Efficacy — GTPγS binding: 72–75% efficacy (EC₅₀ 97–193 nM); cAMP accumulation: 105% efficacy (EC₅₀ 76 nM); β-arrestin2 recruitment: ≤10% efficacy (EC₅₀ >10,000 nM).

Receptor Binding Profile

• MOR Affinity (Kᵢ): 11 nM — high affinity, primary target
• KOR Affinity (Kᵢ): 68 nM — moderate kappa-opioid receptor activity
• DOR Affinity (Kᵢ): >10,000 nM — essentially no delta-opioid receptor activity

Pharmacokinetics

• Oral Bioavailability: 69% — suitable for oral dosing study designs
• CNS Penetration: Efficiently crosses the blood–brain barrier
• Elimination Half-Life: Approximately 6 hours
• Lipophilicity: log P = 4.75 (highly lipophilic)
• Duration: Longer duration of action than morphine or fentanyl at equivalent doses

Chemical Data

• Molecular Formula: C₁₉H₁₈Cl₃N₃O
• Molar Mass: 410.72 g·mol⁻¹
• Class: Piperidinylbenzimidazolone (piperidine-benzimidazole derivative)
• Format: 10ct tablets

Research Context

• Tolerance & Withdrawal Research — SR-17018 is studied for its atypical tolerance profile and reduced withdrawal symptom intensity relative to conventional MOR agonists, making it a useful tool compound in opioid dependence research.
• Opioid Discontinuation Studies — Investigated as a research tool for understanding opioid tolerance reversal and the pharmacological basis of withdrawal management across opioid classes including fentanyl, heroin, methadone, and buprenorphine.
• Safety Pharmacology — Studied for its favorable therapeutic window profile relative to classical opioids, particularly regarding respiratory depression parameters.

Quality Assurance

White Light research compounds are manufactured under controlled conditions to ensure consistent compound integrity and batch-to-batch reproducibility for reliable research outcomes.

⚠ FOR LABORATORY RESEARCH USE ONLY. Not for human consumption. Not FDA-approved. Not a dietary supplement. SR-17018 has not been formally studied in humans and its safety profile in humans is unknown. Handle only by trained research personnel in accordance with applicable institutional protocols.